Elisa Brietzke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8472413/publications.pdf

Version: 2024-02-01

284 papers 12,421 citations

28190 55 h-index 95 g-index

293 all docs

293 docs citations

times ranked

293

15021 citing authors

#	Article	IF	CITATIONS
1	Understanding and navigating the repercussions of the politically polarized climate in mental health. Trends in Psychiatry and Psychotherapy, 2023, , .	0.4	О
2	Nutrition and bipolar disorder: a systematic review. Nutritional Neuroscience, 2023, 26, 637-651.	1.5	12
3	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 100-110.	2.3	9
4	Comparing mortality from covid-19 to mortality due to overdose: A micromort analysis. Journal of Affective Disorders, 2022, 296, 514-521.	2.0	10
5	What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines. Journal of Affective Disorders, 2022, 298, 565-576.	2.0	8
6	Unraveiling the correlation among neurodevelopmental and inflammatory biomarkers in patients with chronic schizophrenia. Nordic Journal of Psychiatry, 2022, 76, 559-564.	0.7	1
7	Misinformation in nutrition through the case of coconut oil: An online before-and-after study. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1375-1384.	1.1	4
8	Novel therapeutic approaches targeting oxidative stress in mood disorders. , 2022, , 1-17.		0
9	A call for improving lithium literacy among clinicians and patients. International Journal of Bipolar Disorders, 2022, 10, 5.	0.8	7
10	Microbiome abnormalities as a possible link between diabetes mellitus and mood disorders: Pathophysiology and implications for treatment. Neuroscience and Biobehavioral Reviews, 2022, 137, 104640.	2.9	4
11	Is subthreshold depression in adolescence clinically relevant?. Journal of Affective Disorders, 2022, 309, 123-130.	2.0	26
12	A Possible Antidepressive Effect of Dietary Interventions: Emergent Findings and Research Challenges. Current Treatment Options in Psychiatry, 2022, 9, 151-162.	0.7	5
13	Smartphoneâ€based interventions in bipolar disorder: Systematic review and metaâ€analyses of efficacy. A position paper from the International Society for Bipolar Disorders (<scp>ISBD</scp>) Big Data Task Force. Bipolar Disorders, 2022, 24, 580-614.	1.1	18
14	Psychiatric profile and quality of life of subjects with excess weight treated with transcranial direct current stimulation combined with a hypocaloric diet. Nutritional Neuroscience, 2021, 24, 919-926.	1.5	4
15	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Molecular Psychiatry, 2021, 26, 2590-2604.	4.1	16
16	Characterizing the gut microbiota in adults with bipolar disorder: a pilot study. Nutritional Neuroscience, 2021, 24, 173-180.	1.5	34
17	Cannabis and Inflammatory Mediators. European Addiction Research, 2021, 27, 16-24.	1.3	14
18	Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 105, 110126.	2.5	12

#	Article	IF	CITATIONS
19	Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. Journal of Psychiatric Research, 2021, 133, 82-92.	1.5	27
20	Effects of infliximab on brain neurochemistry of adults with bipolar depression. Journal of Affective Disorders, 2021, 281, 61-66.	2.0	7
21	Impairments in Peripheral Blood T Effector and T Regulatory Lymphocytes in Bipolar Disorder Are Associated with Staging of Illness and Anti-cytomegalovirus IgG Levels. Molecular Neurobiology, 2021, 58, 229-242.	1.9	29
22	Should systematic reviews and meta-analysis include data from preprints?. Trends in Psychiatry and Psychotherapy, 2021, , .	0.4	0
23	Peripheral inflammatory biomarkers define biotypes of bipolar depression. Molecular Psychiatry, 2021, 26, 3395-3406.	4.1	19
24	Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9). Journal of Psychiatric Research, 2021, 135, 311-317.	1.5	15
25	Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review. Journal of Psychiatric Research, 2021, 137, 426-436.	1.5	27
26	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. American Journal of Psychiatry, 2021, 178, 383-399.	4.0	270
27	Is Obesity A Determinant Of Success With Pharmacological Treatment For Depression? A Systematic Review, Meta-Analysis And Meta-Regression Journal of Affective Disorders, 2021, 287, 54-68.	2.0	17
28	Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries. Journal of Affective Disorders, 2021, 290, 364-377.	2.0	159
29	The importance of countertransference in the clinical care of individuals during acute phases of bipolar disorder. Bipolar Disorders, 2021, 23, 850-851.	1.1	1
30	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. Bipolar Disorders, 2021, 23, 659-678.	1.1	27
31	Why do medications with little or no efficacy continue to be prescribed in the management of patients with bipolar disorder?. Bipolar Disorders, 2021, 23, 541-543.	1.1	2
32	Clinical effectiveness of non-TMS neurostimulation in depression: Clinical trials from 2010 to 2020. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110287.	2.5	6
33	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	4.1	23
34	Vitamin D, Depressive Symptoms, and Covid-19 Pandemic. Frontiers in Neuroscience, 2021, 15, 670879.	1.4	4
35	Metabolic profiling for water-soluble metabolites in patients with schizophrenia and healthy controls in a Chinese population: A case-control study. World Journal of Biological Psychiatry, 2020, 21, 357-367.	1.3	16
36	The effect of caloric restriction on working memory in healthy non-obese adults. CNS Spectrums, 2020, 25, 2-8.	0.7	46

#	Article	IF	Citations
37	Socioeconomic status in children is associated with spontaneous activity in right superior temporal gyrus. Brain Imaging and Behavior, 2020, 14, 961-970.	1.1	7
38	Inflammation, brain structure and cognition interrelations among individuals with differential risks for bipolar disorder. Brain, Behavior, and Immunity, 2020, 83, 192-199.	2.0	11
39	Barriers to care and psychopathology among Bolivian migrants living in São Paulo, Brazil. Transcultural Psychiatry, 2020, 57, 71-80.	0.9	7
40	A discussion of potential clinical markers predicting anti-inflammatory treatment response in individuals with major depression. Brain, Behavior, and Immunity, 2020, 83, 3-4.	2.0	0
41	Parsing metabolic heterogeneity in mood disorders: A hypothesisâ€driven cluster analysis of glucose and insulin abnormalities. Bipolar Disorders, 2020, 22, 79-88.	1.1	10
42	Are serum brain-derived neurotrophic factor concentrations related to brain structure and psychopathology in late childhood and early adolescence?. CNS Spectrums, 2020, 25, 790-796.	0.7	1
43	Neuropeptides and oligopeptidases in schizophrenia. Neuroscience and Biobehavioral Reviews, 2020, 108, 679-693.	2.9	24
44	The effect of transcranial direct current stimulation along with a hypocaloric diet on weight loss in excessive weight people: A pilot randomized clinical trial. Clinical Nutrition ESPEN, 2020, 40, 68-76.	0.5	8
45	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. Schizophrenia Research, 2020, 230, 104-107.	1.1	6
46	Clinical correlates of high burden of general medical comorbidities in patients with bipolar disorder. Journal of Affective Disorders Reports, 2020, 1, 100001.	0.9	0
47	Bipolar disorders. Lancet, The, 2020, 396, 1841-1856.	6.3	419
48	From Speech Illusions to Onset of Psychotic Disorder: Applying Network Analysis to an Experimental Measure of Aberrant Experiences. Schizophrenia Bulletin Open, 2020, 1, .	0.9	3
49	Allostatic load, emotional hyperâ€reactivity, and functioning in individuals with bipolar disorder. Bipolar Disorders, 2020, 22, 711-721.	1.1	17
50	The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. Journal of Affective Disorders, 2020, 274, 903-910.	2.0	70
51	Caloric restriction, resting metabolic rate and cognitive performance in Non-obese adults: A post-hoc analysis from CALERIE study. Journal of Psychiatric Research, 2020, 128, 16-22.	1.5	15
52	Effect of body anthropometrics on brain structure of offspring of parents with bipolar disorder. Journal of Psychiatric Research, 2020, 124, 137-142.	1.5	1
53	Gene expression changes associated with trajectories of psychopathology in a longitudinal cohort of children and adolescents. Translational Psychiatry, 2020, 10, 99.	2.4	3
54	Leptin mediates improvements in cognitive function following treatment with infliximab in adults with bipolar depression. Psychoneuroendocrinology, 2020, 120, 104779.	1.3	11

#	Article	IF	CITATIONS
55	Association of history of adverse childhood experiences with irritable bowel syndrome (IBS) in individuals with mood disorders. Psychiatry Research, 2020, 288, 112967.	1.7	6
56	Three insights on psychoneuroimmunology of mood disorders to be taken from the COVID-19 pandemic. Brain, Behavior, & Immunity - Health, 2020, 5, 100076.	1.3	18
57	What is bipolar disorder? A disease model of dysregulated energy expenditure. Neuroscience and Biobehavioral Reviews, 2020, 113, 529-545.	2.9	15
58	Mental, emotional, and behavioral effects of ketogenic diet for non-epileptic neuropsychiatric conditions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 102, 109947.	2.5	14
59	Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression. Cells, 2020, 9, 895.	1.8	36
60	Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. Brain, Behavior, and Immunity, 2020, 88, 631-639.	2.0	44
61	Exploring the mechanisms of action of the antidepressant effect of the ketogenic diet. Reviews in the Neurosciences, 2020, 31, 637-648.	1.4	30
62	Using the Online Psychotherapy Tool to Address Mental Health Problems in the Context of the COVID-19 Pandemic: Protocol for an Electronically Delivered Cognitive Behavioral Therapy Program. JMIR Research Protocols, 2020, 9, e24913.	0.5	23
63	Development and implementation of guidelines for the management of depression: a systematic review. Bulletin of the World Health Organization, 2020, 98, 683-697H.	1.5	25
64	The potential anti-depressant properties of dexmedetomidine infusion: a review of mechanistic, preclinical, and clinical evidence. Reviews in the Neurosciences, 2020, 31, 649-658.	1.4	3
65	Insights into the Effects of Crack Abuse on the Human Metabolome Using a NMR Approach. Journal of Proteome Research, 2019, 18, 341-348.	1.8	17
66	Peripheral interleukin-6 levels and working memory in non-obese adults: A post-hoc analysis from the CALERIE study. Nutrition, 2019, 58, 18-22.	1.1	8
67	Integrating digital phenotyping in clinical characterization of individuals with mood disorders. Neuroscience and Biobehavioral Reviews, 2019, 104, 223-230.	2.9	38
68	Teaching how to deliver bad news: a systematic review. Revista Bioetica, 2019, 27, 326-340.	0.0	19
69	Genetic risk for Alzheimer's disease and functional brain connectivity in children and adolescents. Neurobiology of Aging, 2019, 82, 10-17.	1.5	23
70	Association between diabetes and mood disorders and the potential use of anti-hyperglycemic agents as antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 95, 109720.	2.5	35
71	Machine learning and big data analytics in bipolar disorder: A position paper from the International Society for Bipolar Disorders Big Data Task Force. Bipolar Disorders, 2019, 21, 582-594.	1.1	74
72	Detecting multiple differentially methylated CpG sites and regions related to dimensional psychopathology in youths. Clinical Epigenetics, 2019, 11, 146.	1.8	13

#	Article	IF	CITATIONS
73	Intra-individual variability in animal models of bipolar disorder. International Journal of Bipolar Disorders, 2019, 7, 9.	0.8	1
74	Attenuated inflammatory response of monocyte-derived macrophage from patients with BD: a preliminary report. International Journal of Bipolar Disorders, 2019, 7, 13.	0.8	16
75	Peripheral biomarkers allow differential diagnosis between schizophrenia and bipolar disorder. Journal of Psychiatric Research, 2019, 119, 67-75.	1.5	31
76	Acute neuroinflammation elicited by TLR-3 systemic activation combined with early life stress induces working memory impairments in male adolescent mice. Behavioural Brain Research, 2019, 376, 112221.	1.2	16
77	Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study. Translational Psychiatry, 2019, 9, 19.	2.4	44
78	Effort-based decision-making is affected by overweight/obesity in major depressive disorder. Journal of Affective Disorders, 2019, 256, 221-227.	2.0	16
79	Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression. JAMA Psychiatry, 2019, 76, 783.	6.0	135
80	Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI study. European Psychiatry, 2019, 59, 52-59.	0.1	19
81	Stress, epigenetics and depression: A systematic review. Neuroscience and Biobehavioral Reviews, 2019, 102, 139-152.	2.9	246
82	Pharmacological treatment for insomnia in patients with major depressive disorder. Expert Opinion on Pharmacotherapy, 2019, 20, 1341-1349.	0.9	13
83	Advances and challenges in development of precision psychiatry through clinical metabolomics on mood and psychotic disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 93, 182-188.	2.5	23
84	Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia. Schizophrenia Research, 2019, 208, 202-208.	1.1	14
85	Emotional intelligence and schizophrenia spectrum disorders: a critical review. Trends in Psychiatry and Psychotherapy, 2019, 41, 94-102.	0.4	5
86	Does obesity and diabetes mellitus metastasize to the brain? "Metaboptosis―and implications for drug discovery and development. CNS Spectrums, 2019, 24, 467-469.	0.7	5
87	A critical literature review on emotional intelligence in addiction. Trends in Psychiatry and Psychotherapy, 2019, 41, 87-93.	0.4	11
88	Suicidal behavior among substance users: data from the Second Brazilian National Alcohol and Drug Survey (II BNADS). Revista Brasileira De Psiquiatria, 2019, 41, 437-440.	0.9	30
89	The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 387-404.	2.5	51
90	Association between spontaneous activity of the default mode network hubs and leukocyte telomere length in late childhood and early adolescence. Journal of Psychosomatic Research, 2019, 127, 109864.	1,2	2

#	Article	IF	Citations
91	Serum metabolic profiling using small molecular waterâ€soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre–postâ€treatment design. Psychiatry and Clinical Neurosciences, 2019, 73, 100-108.	1.0	20
92	Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 1-7.	2.5	30
93	Hypersomnia and Bipolar Disorder: A systematic review and meta-analysis of proportion. Journal of Affective Disorders, 2019, 246, 659-666.	2.0	20
94	The long-term effect of bariatric surgery on depression and anxiety. Journal of Affective Disorders, 2019, 246, 886-894.	2.0	117
95	Hiccups amelioration following a transcranial direct current stimulation protocol targeting central structures. Australian and New Zealand Journal of Psychiatry, 2019, 53, 477-478.	1.3	1
96	The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. European Neuropsychopharmacology, 2019, 29, 137-146.	0.3	19
97	Cognitive impairment in major depressive disorder. CNS Spectrums, 2019, 24, 22-29.	0.7	125
98	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. CNS Spectrums, 2019, 24, 154-162.	0.7	18
99	A pilot case-control study on the association between N-acetyl derivatives in serum and first-episode schizophrenia. Psychiatry Research, 2019, 272, 36-41.	1.7	8
100	Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 109-117.	2.5	93
101	Heterotypic trajectories of dimensional psychopathology across the lifespan: the case of youthâ€onset attention deficit/hyperactivity disorder. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2019, 60, 533-544.	3.1	20
102	Comparison of serum essential trace metals between patients with schizophrenia and healthy controls. Journal of Trace Elements in Medicine and Biology, 2019, 51, 79-85.	1.5	32
103	Oligopeptidases activity in bipolar disorder: Ndel1 and angiotensin I converting enzyme. Journal of Affective Disorders, 2019, 244, 67-70.	2.0	10
104	Peripheral levels of superoxide dismutase and glutathione peroxidase in youths in ultra-high risk for psychosis: a pilot study. CNS Spectrums, 2019, 24, 333-337.	0.7	14
105	New-onset psychiatric symptoms following intracranial meningioma in a patient with schizophrenia: a case study. Revista Brasileira De Psiquiatria, 2019, 41, 91-92.	0.9	1
106	ls bipolar disorder associated with premature aging?. Trends in Psychiatry and Psychotherapy, 2019, 41, 315-317.	0.4	4
107	Attenuated Psychosis Syndromes Among Brazilian Youth and Young Adults: Early Identification and Intervention., 2019,, 279-288.		0
108	Polygenic Risk Score for Alzheimer's Disease: Implications for Memory Performance and Hippocampal Volumes in Early Life. American Journal of Psychiatry, 2018, 175, 555-563.	4.0	75

#	Article	IF	CITATIONS
109	Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?. Neuropharmacology, 2018, 136, 335-342.	2.0	20
110	An immunological age index in bipolar disorder: A confirmatory factor analysis of putative immunosenescence markers and associations with clinical characteristics. International Journal of Methods in Psychiatric Research, 2018, 27, e1614.	1.1	15
111	The impact of body mass index in gene expression of reelin pathway mediators in individuals with schizophrenia and mood disorders: A post-mortem study. Journal of Psychiatric Research, 2018, 102, 186-191.	1.5	5
112	Accessing Gene Expression in Treatment-Resistant Schizophrenia. Molecular Neurobiology, 2018, 55, 7000-7008.	1.9	23
113	Non-invasive brain stimulation for negative symptoms in schizophrenia: An updated systematic review and meta-analysis. Schizophrenia Research, 2018, 197, 34-44.	1.1	76
114	Effects of the brain-derived neurotropic factor variant Val66Met on cortical structure in late childhood and early adolescence. Journal of Psychiatric Research, 2018, 98, 51-58.	1.5	11
115	Targeting cytokines in reduction of depressive symptoms: A comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 83, 86-91.	2.5	54
116	Alice in Wonderland syndrome secondary to optical neuromyelitis caused by varicella. Australian and New Zealand Journal of Psychiatry, 2018, 52, 805-806.	1.3	4
117	The differential association between history of childhood sexual abuse and body mass index in early and late stages of bipolar disorder. Journal of Affective Disorders, 2018, 227, 214-218.	2.0	17
118	Leukocyte telomere length variation in different stages of schizophrenia. Journal of Psychiatric Research, 2018, 96, 218-223.	1.5	25
119	Gluten related illnesses and severe mental disorders: a comprehensive review. Neuroscience and Biobehavioral Reviews, 2018, 84, 368-375.	2.9	21
120	Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review. Journal of Affective Disorders, 2018, 227, 406-415.	2.0	91
121	Long Sleep Duration, Insomnia, and Insomnia With Short Objective Sleep Duration Are Independently Associated With Short Telomere Length. Journal of Clinical Sleep Medicine, 2018, 14, 2037-2045.	1.4	30
122	Expression of dopamine signaling genes in the post-mortem brain of individuals with mental illnesses is moderated by body mass index and mediated by insulin signaling genes. Journal of Psychiatric Research, 2018, 107, 128-135.	1.5	17
123	Preliminary results from Brazil's first recovery housing program. Trends in Psychiatry and Psychotherapy, 2018, 40, 285-291.	0.4	3
124	Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder. Frontiers in Psychiatry, 2018, 9, 655.	1.3	150
125	Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. Therapeutic Advances in Psychopharmacology, 2018, 8, 337-348.	1.2	50
126	Effect of male-specific childhood trauma on telomere length. Journal of Psychiatric Research, 2018, 107, 104-109.	1.5	11

#	Article	IF	CITATIONS
127	Letter to the editor: Inadequate evidence to support improved patient outcomes with combinatorial pharmacogenomics. Journal of Psychiatric Research, 2018, 107, 136-137.	1.5	1
128	Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case–control study. Amino Acids, 2018, 50, 1013-1023.	1.2	36
129	Evidence supporting a mechanistic role of sirtuins in mood and metabolic disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 86, 95-101.	2.5	34
130	Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network metaâ€analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2467-2471.	2.2	76
131	Mental Disorders, Antidepressants, and Type 2 Diabetes. JAMA Pediatrics, 2018, 172, 703.	3.3	2
132	Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neuroscience and Biobehavioral Reviews, 2018, 94, 11-16.	2.9	102
133	Predicting antidepressant response using early changes in cognition: A systematic review. Behavioural Brain Research, 2018, 353, 154-160.	1.2	28
134	Stress, trauma, and posttraumatic stress disorder in migrants: a comprehensive review. Revista Brasileira De Psiquiatria, 2018, 40, 220-225.	0.9	92
135	Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. International Journal of Environmental Research and Public Health, 2018, 15, 771.	1.2	80
136	Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?. Brain, Behavior, and Immunity, 2018, 73, 115-124.	2.0	90
137	Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review. Journal of Affective Disorders, 2018, 241, 519-532.	2.0	179
138	Leptin and adiponectin levels in major depressive disorder: A systematic review and meta-analysis. Journal of Affective Disorders, 2018, 238, 101-110.	2.0	59
139	Therapeutic potential of JAK/STAT pathway modulation in mood disorders. Reviews in the Neurosciences, 2018, 30, 1-7.	1.4	35
140	Coronary calcium score as an expression of multisystemic progression of bipolar disorder. Revista Brasileira De Psiquiatria, 2018, 40, 459-460.	0.9	2
141	Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. Annals of Clinical Psychiatry, 2018, 30, 38-50.	0.6	28
142	Analytical approaches for lipidomics and its potential applications in neuropsychiatric disorders. World Journal of Biological Psychiatry, 2017, 18, 506-520.	1.3	34
143	Lipidomics, Biomarkers, and Schizophrenia: A Current Perspective. Advances in Experimental Medicine and Biology, 2017, 965, 265-290.	0.8	15
144	Adolescents at clinical-high risk for psychosis: Circadian rhythm disturbances predict worsened prognosis at 1-year follow-up. Schizophrenia Research, 2017, 189, 37-42.	1,1	66

#	Article	IF	Citations
145	Shorter leukocyte telomere length in patients at ultra high risk for psychosis. European Neuropsychopharmacology, 2017, 27, 538-542.	0.3	25
146	Microbiota abnormalities and the therapeutic potential of probiotics in the treatment of mood disorders. Reviews in the Neurosciences, 2017, 28, 739-749.	1.4	34
147	Plasma copeptin and metabolic dysfunction in individuals with bipolar disorder. Psychiatry and Clinical Neurosciences, 2017, 71, 624-636.	1.0	12
148	1H-NMR, 1H-NMR T2-edited, and 2D-NMR in bipolar disorder metabolic profiling. International Journal of Bipolar Disorders, 2017, 5, 23.	0.8	23
149	A pilot, openâ€label, 8â€week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disorders, 2017, 19, 198-213.	1.1	39
150	Gene expression in blood of children and adolescents: Mediation between childhood maltreatment and major depressive disorder. Journal of Psychiatric Research, 2017, 92, 24-30.	1.5	25
151	NMR Spectroscopy Metabolomics Applied to Crack Cocaine Users and Patients with Schizophrenia: Similar Behavior but Different Molecular Causes. ChemistrySelect, 2017, 2, 2927-2930.	0.7	4
152	Recent advances in lipidomics: Analytical and clinical perspectives. Prostaglandins and Other Lipid Mediators, 2017, 128-129, 8-16.	1.0	84
153	Metabolomics and lipidomics analyses by 1H nuclear magnetic resonance of schizophrenia patient serum reveal potential peripheral biomarkers for diagnosis. Schizophrenia Research, 2017, 185, 182-189.	1.1	35
154	Medical comorbidity in bipolar disorder: The link with metabolic-inflammatory systems. Journal of Affective Disorders, 2017, 211, 99-106.	2.0	87
155	Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Archives of Women's Mental Health, 2017, 20, 713-719.	1.2	35
156	Gene Expression Alterations Related To Mania And Psychotic Symptoms In Peripheral Blood of Patients with A First Episode of Psychosis. European Neuropsychopharmacology, 2017, 27, S403-S404.	0.3	0
157	<scp>BDNF</scp> and <scp>BMI</scp> effects on brain structures of bipolar offspring: results from the global mood and brain science initiative. Acta Psychiatrica Scandinavica, 2017, 136, 607-614.	2.2	16
158	A preliminary study of bipolar disorder type I by mass spectrometry-based serum lipidomics. Psychiatry Research, 2017, 258, 268-273.	1.7	33
159	Nâ€acetylcysteine in the treatment of craving in substance use disorders: Systematic review and metaâ€analysis. American Journal on Addictions, 2017, 26, 660-666.	1.3	58
160	Treatment with a GLPâ^'1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. European Neuropsychopharmacology, 2017, 27, 1153-1162.	0.3	49
161	Sudden unexpected death in bipolar disorder. Journal of Affective Disorders, 2017, 223, 8-9.	2.0	2
162	Perinatal complications, lipid peroxidation, and mental health problems in a large community pediatric sample. European Child and Adolescent Psychiatry, 2017, 26, 521-529.	2.8	10

#	Article	IF	Citations
163	Selfish brain and selfish immune system interplay: A theoretical framework for metabolic comorbidities of mood disorders. Neuroscience and Biobehavioral Reviews, 2017, 72, 43-49.	2.9	25
164	Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. Journal of Affective Disorders, 2017, 207, 114-120.	2.0	110
165	Theory of Mind in Substance Users: A Systematic Minireview. Substance Use and Misuse, 2017, 52, 127-133.	0.7	20
166	Differential Impact of Obesity on CD69 Expression in Individuals with Bipolar Disorder and Healthy Controls. Molecular Neuropsychiatry, 2017, 3, 192-196.	3.0	6
167	A critical review of trials of transcranial direct current stimulation and trigeminal nerve stimulation for depression: the issue of treatment-emergent mania. Trends in Psychiatry and Psychotherapy, 2017, 39, 48-53.	0.4	11
168	Impact of inequalities in health care on the mortality risk of individuals with severe mental illnesses. Revista Brasileira De Psiquiatria, 2017, 39, 193-194.	0.9	4
169	Challenges and developments in research of the early stages of bipolar disorder. Revista Brasileira De Psiquiatria, 2016, 38, 329-337.	0.9	10
170	Hair cortisol in drug-naÃ-ve first-episode individuals with psychosis. Revista Brasileira De Psiquiatria, 2016, 38, 11-16.	0.9	15
171	Measuring child maltreatment using multi-informant survey data: a higher-order confirmatory factor analysis. Trends in Psychiatry and Psychotherapy, 2016, 38, 23-32.	0.4	22
172	The effect of the severity of obstructive sleep apnea syndrome on telomere length. Oncotarget, 2016, 7, 69216-69224.	0.8	27
173	Is semantic verbal fluency impairment explained by executive function deficits in schizophrenia?. Revista Brasileira De Psiquiatria, 2016, 38, 121-126.	0.9	27
174	Brainâ€derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course. Bipolar Disorders, 2016, 18, 373-378.	1.1	20
175	Serum copeptin in children exposed to maltreatment. Psychiatry and Clinical Neurosciences, 2016, 70, 434-441.	1.0	12
176	Inflammation, neurotrophism and oxidative stress and childhood psychopathology in a large community sample. Acta Psychiatrica Scandinavica, 2016, 133, 122-132.	2.2	8
177	Lean economies and innovation in mental health systems. Lancet, The, 2016, 387, 1356-1358.	6.3	13
178	Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis. Translational Psychiatry, 2016, 6, e908-e908.	2.4	26
179	Interâ€relation between brainâ€derived neurotrophic factor and antioxidant enzymes in bipolar disorder. Bipolar Disorders, 2016, 18, 433-439.	1,1	11
180	Peripheral immuno-inflammatory abnormalities in ultra-high risk of developing psychosis. Schizophrenia Research, 2016, 176, 191-195.	1.1	46

#	Article	IF	CITATIONS
181	Distinct behavioral and immunoendocrine parameters during crack cocaine abstinence in women reporting childhood abuse and neglect. Drug and Alcohol Dependence, 2016, 167, 140-148.	1.6	29
182	An integrative approach to investigate the respective roles of single-nucleotide variants and copy-number variants in Attention-Deficit/Hyperactivity Disorder. Scientific Reports, 2016, 6, 22851.	1.6	18
183	Crack cocaine addiction, early life stress and accelerated cellular aging among women. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 71, 83-89.	2.5	34
184	Association of serum interleukin-6 with mental health problems in children exposed to perinatal complications and social disadvantage. Psychoneuroendocrinology, 2016, 71, 94-101.	1.3	7
185	Bipolar disorder course, impaired glucose metabolism and antioxidant enzymes activities: A preliminary report. Journal of Psychiatric Research, 2016, 80, 38-44.	1.5	14
186	Antiâ€inflammatory agents in the treatment of bipolar depression: a systematic review and metaâ€analysis. Bipolar Disorders, 2016, 18, 89-101.	1.1	153
187	Adipokines, metabolic dysfunction and illness course in bipolar disorder. Journal of Psychiatric Research, 2016, 74, 63-69.	1.5	40
188	Impaired glucose metabolism moderates the course of illness in bipolar disorder. Journal of Affective Disorders, 2016, 195, 57-62.	2.0	30
189	Post-traumatic stress disorder and interleukin 6 – Authors' reply. Lancet Psychiatry,the, 2016, 3, 202.	3.7	1
190	Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic NaÃ-ve First Episode Psychosis. Molecular Neurobiology, 2016, 53, 5701-5709.	1.9	59
191	The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 65, 134-144.	2.5	137
192	Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders. International Journal of Neuropsychopharmacology, 2016, 19, pyv096.	1.0	80
193	Socioeconomic Disadvantage Moderates the Association between Peripheral Biomarkers and Childhood Psychopathology. PLoS ONE, 2016, 11, e0160455.	1.1	14
194	Hippocampus size does not correlate with body mass index in bipolar disorder. Revista Brasileira De Psiquiatria, 2016, 38, 86-87.	0.9	4
195	Circadian rhythm disturbances and conversion to psychosis in ultra high-risk youth. Revista Brasileira De Psiquiatria, 2016, 38, 178-179.	0.9	4
196	It is time to prepare mental health services to attend to migrants and refugees. Revista Brasileira De Psiquiatria, 2016, 38, 263-264.	0.9	6
197	Clinical characteristics and influence of childhood trauma on the prodrome of bipolar disorder. Revista Brasileira De Psiquiatria, 2015, 37, 280-288.	0.9	19
198	Determinants of adherence to treatment in first-episode psychosis: a comprehensive review. Revista Brasileira De Psiquiatria, 2015, 37, 168-176.	0.9	61

#	Article	IF	Citations
199	Early stages of bipolar disorder: characterization and strategies for early intervention. Revista Brasileira De Psiquiatria, 2015, 37, 343-349.	0.9	19
200	Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry,the, 2015, 2, 1002-1012.	3.7	520
201	Is there a "metabolic-mood syndrome� A review of the relationship between obesity and mood disorders. Neuroscience and Biobehavioral Reviews, 2015, 52, 89-104.	2.9	238
202	Effects of Risperidone on Cytokine Profile in Drug-Naive First-Episode Psychosis. International Journal of Neuropsychopharmacology, 2015, 18, pyu042-pyu042.	1.0	77
203	High risk cohort study for psychiatric disorders in childhood: rationale, design, methods and preliminary results. International Journal of Methods in Psychiatric Research, 2015, 24, 58-73.	1.1	148
204	Is religiosity a protective factor against suicidal behavior in bipolar I outpatients?. Journal of Affective Disorders, 2015, 186, 156-161.	2.0	27
205	Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug na \tilde{A} -ve first episode psychosis. Schizophrenia Research, 2015, 166, 225-230.	1.1	34
206	Circadian rest–activity rhythm in individuals at risk for psychosis and bipolar disorder. Schizophrenia Research, 2015, 168, 50-55.	1.1	57
207	Gene expression analysis in blood of ultra-high risk subjects compared to first-episode of psychosis patients and controls. World Journal of Biological Psychiatry, 2015, 16, 441-446.	1.3	14
208	Oxidative stress in drug na \tilde{A} -ve first episode psychosis and antioxidant effects of risperidone. Journal of Psychiatric Research, 2015, 68, 210-216.	1.5	51
209	Effects of depression on the cytokine profile in drug na \tilde{A} ve first-episode psychosis. Schizophrenia Research, 2015, 164, 53-58.	1.1	48
210	Abnormalities in sleep patterns in individuals at risk for psychosis and bipolar disorder. Schizophrenia Research, 2015, 169, 262-267.	1.1	54
211	High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. World Journal of Biological Psychiatry, 2015, 16, 422-429.	1.3	69
212	Increased expression of NDEL1 and MBP genes in the peripheral blood of antipsychotic-na \tilde{A} -ve patients with first-episode psychosis. European Neuropsychopharmacology, 2015, 25, 2416-2425.	0.3	23
213	Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. Journal of Affective Disorders, 2015, 188, 149-159.	2.0	126
214	Angiotensin converting enzyme activity is positively associated with IL-17a levels in patients with schizophrenia. Psychiatry Research, 2015, 229, 702-707.	1.7	22
215	Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls. Psychiatry Research - Neuroimaging, 2015, 234, 84-89.	0.9	16
216	Omics-based depression and inflammation research. Revista Brasileira De Psiquiatria, 2015, 37, 1-2.	0.9	8

#	Article	IF	Citations
217	The Putative Impact of Metabolic Health on Default Mode Network Activity and Functional Connectivity in Neuropsychiatric Disorders. CNS and Neurological Disorders - Drug Targets, 2015, 13, 1750-1758.	0.8	13
218	Childhood Trauma Questionnaire (CTQ) in Brazilian Samples of Different Age Groups: Findings from Confirmatory Factor Analysis. PLoS ONE, 2014, 9, e87118.	1.1	108
219	Public school teachers' perceptions about mental health. Revista De Saude Publica, 2014, 48, 940-948.	0.7	10
220	Systematic review of N-acetylcysteine in the treatment of addictions. Revista Brasileira De Psiquiatria, 2014, 36, 168-175.	0.9	63
221	Influence of personality traits in coping skills in individuals with bipolar disorder. Revista De Psiquiatria Clinica, 2014, 41, 95-100.	0.6	2
222	Functioning in early and late stages of schizophrenia. Trends in Psychiatry and Psychotherapy, 2014, 36, 209-213.	0.4	10
223	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	2.3	229
224	Advancing biomarker research: utilizing â€~Big Data' approaches for the characterization and prevention of bipolar disorder. Bipolar Disorders, 2014, 16, 531-547.	1.1	57
225	Early life stress and tumor necrosis factor superfamily in crack cocaine withdrawal. Journal of Psychiatric Research, 2014, 53, 180-186.	1.5	25
226	The theory of bipolar disorder as an illness of accelerated aging: Implications for clinical care and research. Neuroscience and Biobehavioral Reviews, 2014, 42, 157-169.	2.9	146
227	Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression. NeuroImmunoModulation, 2014, 21, 131-139.	0.9	40
228	Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. Physiology and Behavior, 2014, 129, 194-198.	1.0	49
229	Childhood maltreatment and inflammatory markers: a systematic review. Acta Psychiatrica Scandinavica, 2014, 129, 180-192.	2.2	329
230	Diabetes Mellitus and Disturbances in Brain Connectivity: A Bidirectional Relationship?. NeuroMolecular Medicine, 2014, 16, 658-668.	1.8	25
231	Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: A follow-up study in antipsychotic-naĀ ve patients with first-episode psychosis. Journal of Psychiatric Research, 2014, 56, 130-136.	1.5	13
232	Manic Symptoms in Youth: Dimensions, Latent Classes, and Associations With Parental Psychopathology. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 625-634.e2.	0.3	16
233	Recognition of bipolar disorder type I before the first manic episode: challenges and developments. Expert Review of Neurotherapeutics, 2013, 13, 795-807.	1.4	11
234	Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. Journal of Psychiatric Research, 2013, 47, 467-471.	1.5	32

#	Article	IF	CITATIONS
235	Do sleep abnormalities and misaligned sleep/circadian rhythm patterns represent early clinical characteristics for developing psychosis in high risk populations?. Neuroscience and Biobehavioral Reviews, 2013, 37, 2631-2637.	2.9	53
236	Selfish brain and neuroprogression in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 43, 66-71.	2.5	22
237	Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. Journal of Psychiatric Research, 2013, 47, 1376-1382.	1.5	84
238	Adipokines during early abstinence of crack cocaine in dependent women reporting childhood maltreatment. Psychiatry Research, 2013, 210, 536-540.	1.7	22
239	First manic episode in a patient with breast cancer. General Hospital Psychiatry, 2013, 35, 681.e13-681.e14.	1.2	1
240	Brain tumor in a patient with attenuated psychosis syndrome. Schizophrenia Research, 2013, 144, 151-152.	1.1	8
241	Bipolar Disorder and Metabolic Syndrome: A Systematic Review. Revista Brasileira De Psiquiatria, 2013, 35, 88-93.	0.9	65
242	Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia. Schizophrenia Research, 2013, 148, 81-86.	1.1	55
243	Is there a role for curcumin in the treatment of bipolar disorder?. Medical Hypotheses, 2013, 80, 606-612.	0.8	20
244	Determinants of adherence to treatment in bipolar disorder: A comprehensive review. Journal of Affective Disorders, 2013, 149, 247-252.	2.0	127
245	Cytokine Alterations in Bipolar Disorder: A Meta-Analysis of 30 Studies. Biological Psychiatry, 2013, 74, 15-25.	0.7	504
246	Adolescents and young adults who are not in employment, education, or training. BMJ, The, 2013, 347, f5270-f5270.	3.0	57
247	Adaptation of the Barriers to Access to Care Evaluation (BACE) scale to the Brazilian social and cultural context. Trends in Psychiatry and Psychotherapy, 2013, 35, 287-291.	0.4	6
248	Translation and adaptation of the Bipolar Prodrome Symptom Scale-Retrospective: Patient Version to Brazilian portuguese. Trends in Psychiatry and Psychotherapy, 2013, 35, 62-75.	0.4	1
249	N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals. Reviews in the Neurosciences, 2012, 23, 353-62.	1.4	22
250	Hair Cortisol and Stressful Life Events Retrospective Assessment in Crack Cocaine Users. American Journal of Drug and Alcohol Abuse, 2012, 38, 535-538.	1.1	36
251	The Association between Childhood Adversity and Components of Metabolic Syndrome in Adults with Mood Disorders: Results from the International Mood Disorders Collaborative Project. International Journal of Psychiatry in Medicine, 2012, 43, 165-177.	0.8	67
252	A theoretical framework informing research about the role of stress in the pathophysiology of bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 1-8.	2.5	43

#	Article	IF	Citations
253	Novel therapeutic targets in depression: Minocycline as a candidate treatment. Behavioural Brain Research, 2012, 235, 302-317.	1.2	162
254	The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. European Psychiatry, 2012, 27, 223-228.	0.1	96
255	Impact of Childhood Stress on Psychopathology. Revista Brasileira De Psiquiatria, 2012, 34, 480-488.	0.9	74
256	Inflammatory cytokines as an underlying mechanism of the comorbidity between bipolar disorder and migraine. Medical Hypotheses, 2012, 78, 601-605.	0.8	24
257	Impact of comorbid migraine on the clinical course of bipolar disorder. Comprehensive Psychiatry, 2012, 53, 809-812.	1.5	25
258	The "selfish brain" hypothesis for metabolic abnormalities in bipolar disorder and schizophrenia. Trends in Psychiatry and Psychotherapy, 2012, 34, 121-128.	0.4	12
259	Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. Journal of Affective Disorders, 2012, 140, 82-91.	2.0	85
260	Cytokines in schizophrenia: Possible role of antiâ€inflammatory medications in clinical and preclinical stages. Psychiatry and Clinical Neurosciences, 2012, 66, 247-260.	1.0	49
261	Insulin dysfunction and allostatic load in bipolar disorder. Expert Review of Neurotherapeutics, 2011, 11, 1017-1028.	1.4	54
262	Therapeutic potential of interleukin-6 antagonism in bipolar disorder. Medical Hypotheses, 2011, 76, 21-23.	0.8	31
263	The role of Wnt signaling and its interaction with diverse mechanisms of cellular apoptosis in the pathophysiology of bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, $2011, 35, 11-17$.	2.5	18
264	Association of biomarkers and depressive symptoms in schizophrenia. Neuroscience Letters, 2011, 505, 282-285.	1.0	38
265	Early intervention in psychosis: a map of clinical and research initiatives in Latin America. Revista Brasileira De Psiquiatria, 2011, 33, s213-s224.	0.9	27
266	Early intervention for bipolar disorder: current imperatives, future directions. Revista Brasileira De Psiquiatria, 2011, 33, s197-s212.	0.9	17
267	Continuing lack of evidence for the psychotic subtyping of PTSD. British Journal of Psychiatry, 2011, 198, 156-156.	1.7	2
268	Longâ€acting injectable risperidone in a bipolar patient submitted to bariatric surgery and intolerant to conventional mood stabilizers. Psychiatry and Clinical Neurosciences, 2011, 65, 205-205.	1.0	10
269	Childhood maltreatment and clinical outcomes of bipolar disorder. Acta Psychiatrica Scandinavica, 2011, 124, 427-434.	2.2	191
270	Clinical correlates of eating disorder comorbidity in women with bipolar disorder type I. Journal of Affective Disorders, 2011, 130, 162-165.	2.0	38

#	Article	IF	CITATIONS
271	Cytokines in Bipolar Disorder: <i>Recent Findings, Deleterious Effects But Promise for Future Therapeutics</i> . CNS Spectrums, 2011, 16, 157-168.	0.7	50
272	A Randomized Controlled Trial of Cognitive Behavioral Group Therapy for Bipolar Disorder. Psychotherapy and Psychosomatics, 2011, 80, 144-150.	4.0	49
273	Letter to the Editor: Adiposity as a possible mediator of low testosterone salivary levels in adolescent boys in prodromal stages of psychosis. Psychological Medicine, 2011, 41, 2010-2012.	2.7	0
274	Interleukin-6 and verbal memory in recurrent major depressive disorder. Neuroendocrinology Letters, 2011, 32, 540-4.	0.2	29
275	A comparison of the symptomatic profile between two consecutive depressive episodes in patients with bipolar disorder type I. Acta Neuropsychiatrica, 2010, 22, 280-283.	1.0	1
276	Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disorders, 2010, 12, 453-454.	1.1	14
277	Increased soluble tumor necrosis factorâ€Î± receptors in patients with major depressive disorder. Psychiatry and Clinical Neurosciences, 2009, 63, 202-208.	1.0	79
278	Abnormalities in serum chemokine levels in euthymic patients with Bipolar Disorder. Brain, Behavior, and Immunity, 2009, 23, 1079-1082.	2.0	119
279	The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1366-1371.	2.5	139
280	Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. Journal of Affective Disorders, 2009, 116, 214-217.	2.0	376
281	TNF- \hat{l}_{\pm} as a molecular target in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1355-1361.	2.5	140
282	Screening for Placental Insufficiency by Transvaginal Uterine Artery Doppler at 22–24 Weeks of Gestation. Fetal Diagnosis and Therapy, 2008, 24, 462-469.	0.6	13
283	Reported Calcium Intake is Reduced in Women with Preeclampsia. Hypertension in Pregnancy, 2006, 25, 229-239.	0.5	18
284	Morte materna em hospital terciário do Rio Grande do Sul - Brasil: um estudo de 20 anos. Revista Brasileira De Ginecologia E Obstetricia, 2003, 25, 431-436.	0.3	18